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Abstract 
Background: The evidence behind recommendations for treatment of iron deficiency (ID) 
following roux-en-y gastric bypass surgery (RYGB) lacks high quality studies. 
Setting: Academic, United States 
Objective: To compare the effectiveness of oral iron supplementation using non-heme versus 
heme iron for treatment of iron deficiency in RYGB patients.  
Methods: In a randomized, single-blind study, women post-RYGB and iron deficient received 
non-heme iron (FeSO4, 195 mg/day) or heme iron (heme-iron-polypeptide, HIP, 31.5 to 94.5 
mg/day) for 8 weeks.  Measures of iron status, including blood concentrations of ferritin, soluble 
transferrin receptor (sTfR), and hemoglobin, were assessed.   
Results:  At baseline, the mean ± standard deviation for age, BMI, and years since surgery of the 
sample was 41.5 ± 6.8 years, 34.4 ± 5.9 kg/m2, and 6.9 ±3.1 years, respectively; and there were 
no differences between FeSO4 (N=6) or HIP (N=8) groups.  Compliance was greater than 94%.  
The study was stopped early due to statistical and clinical differences between groups.  Values 
before and after FeSO4 supplementation, expressed as least square means (95% CI) were: 
hemoglobin, 10.8 (9.8, 11.9) to 13.0 (11.9, 14.0) g/dL; sTfR, 2111 (1556, 2864) to 1270 (934, 
1737) µg/L; ferritin, 4.9 (3.4, 7.2) to 15.5 (10.6, 22.6) µg/L; and sTfR:ferritin ratio, 542 (273, 
1086) to 103 (51, 204); all p < 0.0001.  With HIP supplementation, no change was observed in 
any of the iron status biomarkers (all p>0.05).   
Conclusions:  In accordance with recommendations, oral supplementation using FeSO4, but not 
HIP, was efficacious for treatment of iron deficiency after RYGB.  
ClinicalTrials.gov, NCT 02404012. 
Keywords: iron deficiency, iron supplementation, nutritional complications, bariatric surgery 
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Introduction 
 Bariatric surgery to treat severe obesity is common in the United States today.  About 1.5 
million people have undergone bariatric surgery already, and an additional 200,000 individuals 
undergo the surgery every year (1) . Roux-en-Y gastric bypass (RYGB) is currently one of the 
most popular types of bariatric surgery procedures, comprising 34.2% of all bariatric procedures 
(2).  RYGB promotes significant weight loss through both energy restriction (by reducing the 
size of the stomach, which increases satiety (3-5)) and macronutrient malabsorption (by 
bypassing part of the intestine which is needed for adequate nutrient absorption (6)).  For 
moderately and severely obese individuals, this surgery is effective for weight loss, often after 
they have failed using conventional dieting, and it can reduce the risk of type 2 diabetes, cancer, 
heart attack, stroke, and other obesity-related comorbidities (7, 8).  
 Unfortunately, surgically-induced deficiencies in essential nutrients are prevalent after 
bariatric surgery, and iron deficiency occurs in 10 to 60% of patients after surgery (9-12).  Iron 
plays a critical role in the body, and this sheds light into the signs and symptoms that manifest 
when an individual is iron deficient.  The clinical consequences of iron deficiency in bariatric 
surgery patients have been shown to negatively impact quality of life (13) and include general 
fatigue, weakness, cold intolerance, anemia, hair loss, pica, and cognitive impairments in 
concentration, attention and memory (14-17).  Because of issues such as a lack of monitoring 
and screening, reduced dietary intake of bioavailable iron, poor compliance to prophylactic iron 
supplementation, and poor response to treatment, bariatric surgery patients who develop iron 
deficiency often remain undiagnosed and untreated (1).  Nutritional management of iron status 
needs to be improved for patients to reap the full benefits of bariatric surgery.   
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 The standard of care recommendation for treatment of iron deficiency after bariatric 
surgery, as stated in the clinical practice guidelines, is to provide up to 150-200 mg of oral non-
heme iron daily (18, 19), commonly in the form of ferrous sulfate, ferrous fumarate, or ferrous 
gluconate.  The evidence that supports these recommendations is not ideal since it is based on a 
randomized control trial that evaluated oral ferrous sulfate when used as a prophylactic (20) - as 
opposed to for treatment of overt iron deficiency.  Moreover, in this trial, and in another that did 
not have a comparator group (21), oral iron supplementation did not improve anemia.  Oral iron 
supplementation was also found to be ineffective for resolution of iron deficiency in 
observational studies (17, 22-24).  Since iron deficiency after bariatric surgery appears to be 
refractory to treatment with oral iron supplementation, current guidelines may need to be 
revisited.   
 The ineffectiveness of oral iron supplementation for prevention or treatment of iron 
deficiency may be due to reduced intestinal absorption of iron (25, 26) or to low compliance of 
patients to the regimen (27, 28).  Users of ferrous sulfate and other formulations of non-heme 
iron preparations experience gastrointestinal adverse side effects such as diarrhea and 
constipation because inorganic iron is highly labile (29).  However, in a recent cross-sectional 
study we demonstrated that prophylactic use of oral non-heme iron supplementation was 
adequate for preserving normal iron status following RYGB (30).  In addition, we demonstrated 
that high dietary intake of heme iron was also associated with positive iron status after bariatric 
surgery (30).  In addition, studies assessing intestinal iron absorption in severely obese patients, 
using the stable isotope method which is highly accurate, found that heme iron was two-fold 
higher compared to non-heme iron (25). For this reason, we speculated that oral supplementation 
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with an iron formulation based on heme iron may be better when compared to non-heme iron 
formulations for treatment of deficiency post bariatric surgery.  
 Heme iron polypeptide (HIP) is a novel supplemental formulation of heme iron that 
exists commercially, under the brand name Proferrin ES (Colorado Biolabs Inc., Frederick, CO).  
In healthy subjects, the bioavailability of HIP was greater than that for ferrous sulfate (31), but 
HIP’s effectiveness was comparable to ferrous sulfate when used as a treatment for iron 
deficiency in patients with chronic kidney disease (32).  HIP has not been evaluated in patients 
who have had bariatric surgery.  Therefore the objective of this study was to compare the 
effectiveness of oral supplementation using HIP versus ferrous sulfate for treatment of iron 
deficiency in a bariatric surgery population.  Since ferrous sulfate is the standard of care, we did 
not include a placebo group, which would be unethical.  To our knowledge, this is the first 
randomized clinical trial to provide empirical information regarding oral iron formulations for 
treatment of iron deficiency in bariatric surgery patients, which can be used to inform clinical 
practice guidelines.  The study is registered at ClinicalTrials.gov (NCT 02404012).   
 
Methods 
Participant Recruitment and Eligibility 
 Participants who already had a bariatric surgery procedure, at least six months ago, were 
recruited through the use of a practice-based research database within Indiana Network of Patient 
Care at Regenstrief Institute which is offered through the Research Recruitment Office at the 
Indiana Clinical and Translational Science Institute.  The investigators received approval from 
the Institutional Review Board of Purdue University to conduct the study (#1410015305).  All 
procedures performed in studies involving human participants were in accordance with the 
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ethical standards of the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards.  Informed 
consent was obtained from all individual participants included in the study. 
 A screening visit was used to identify individuals who were eligible for the study.  
Participants visited the Indiana Clinical and Translational Science Institute at Purdue University 
(West Lafayette) or at Indiana University Purdue University at Indianapolis.  Eligibility criteria 
was reviewed and interpreted by a study physician.  Participants were eligible if they were 
women aged 18 to 50 years, who had undergone RYGB at least 6 months previously.  Since we 
were seeking to enroll RYGB patients who were iron deficient, we expected that both recent and 
patients further out from surgery would be eligible for the study.  Women who were under 50 
years of age, but were post- or peri-menopausal (e.g. due to hysterectomy), were included in the 
study.  Individuals were excluded if they were pregnant, had a surgical revision of a bariatric 
procedure, had intravenous (IV) iron greater than one month previously, had been recently 
hospitalized for an acute illness, or were not classified as iron deficient.  A single, reliable 
biochemical indicator that accurately diagnoses iron deficiency does not exist; for this reason, 
using multiple parameters provides the best assessment of iron status (33).  Patients were 
classified as iron deficient if they met at least two of the following conditions at their screening 
visit: 1) ferritin < 20 μg/L (33), 2) total iron binding capacity (TIBC) > 370 μg/dL (33), 3) 
soluble transferrin receptor (sTfR) > 2012 μg/L, and 4) sTfR:ferritin ratio > 500 (33).   
Clinical Biochemistries 
After participant had undergone an overnight fast of at least 8 hours, a blood draw was 
obtained using venipuncture, and blood was collected for analysis of iron status (ferritin, 
hemoglobin, TIBC, and sTfR), as well as copper, zinc, C-reactive protein (CRP), plasma 
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hepcidin, and vitamins B6, B9, and B12.  With the exception of plasma hepcidin which was 
measured using ELISA kit (DRG International, Springfield, NJ, USA), all other laboratory 
assays were undertaken by Mid America Clinical Laboratories (MACL, Indianapolis, IN, USA) 
which is a commercial reference clinical laboratory.  At the end of the screening visit, to ensure 
that other micronutrient deficiencies, besides iron, were prevented or treated, participants were 
provided with a chewable (iron-free) multivitamin / mineral supplement (Centrum Silver, Pfizer 
Inc, Kings Mountain, NC, USA), and instructed to take the multivitamin once daily.  The 
multivitamin provided the following nutrients: 75 mg vitamin C, 2.2 mg vitamin B1, 7 mg 
vitamin B6, 25 mcg vitamin B12, 200 mg calcium, 15 mg zinc, and 2 mg copper.   
 
Description of Intervention 
 The study used a randomized, controlled design, in which participants were randomized 
to receive either the standard of care, ferrous sulfate or HIP for 8 weeks, with follow-up visits 
scheduled at 2, 4 and 8 weeks.  We initially considered testing similar dosages of iron in the two 
formulations, however, heme iron is more bioavailable than non heme iron, 25% versus 10% 
absorption, respectively (34).  In addition, we were informed by our previous study, which found 
that heme iron, when found in food, is a stronger predictor of iron status compared to non-heme 
iron (30).  Therefore, we compared the dose of non-heme iron that is recommended for bariatric 
surgery patients (195 mg non-heme iron/day) (18), to HIP at a dose of 31.5 mg heme iron/day, 
which is the dose recommended by the manufacturer (Colorado Biolabs Inc., Frederick, CO), 
and 1.5 X the dose that was used in an absorption study with healthy subjects (31).   Based on an 
interim analysis, specified in the initial protocol, and conducted after eight patients were enrolled 
in the study, the Data Safety Monitoring Committee advised including higher doses of HIP 
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(containing 63 mg iron/day or 94.5 mg iron/day).  The two additional doses were included in the 
randomization as a 1:1:1:1 allocation ratio.  A web-based site called Stat Trek Random Number 
Generator was used to generate the random allocation sequence.  Throughout the study, 
participants were blinded to their assignment group.  To meet the dose of iron administered, 
patients were instructed to take one pill of HIP or ferrous sulfate three times per day.  In addition 
to the iron supplement, participants were told to continue taking the same daily iron-free 
multivitamin / mineral supplement as they were instructed to take at their screening visit.  Based 
on previous findings from our laboratory, we found that ingestion of iron and vitamin C from 
food and supplements, predicted iron status, but other nutrients, including calcium, did not (30).  
Therefore, we did not provide specific instructions about the mode or timing of ingestion; we 
only asked participants to record, in a medication diary, when they took a supplement and 
whether they took it with food.    
Quality of Formulations 
To ascertain that the amount of iron in the two different supplements was equivalent to 
that reported by the manufacturers, samples of these supplements were analyzed for their iron 
content using inductively-coupled plasma mass spectrometry (35).  For both supplements, the 
amount of iron that was measured was comparable to that reported by the manufacturer (for 
ferrous sulfate, 67.2 mg iron/pill measured versus 65.0 mg/pill reported; for HIP, 11.8 mg 
iron/pill measured versus 10.5 mg reported by manufacturer).  A simple disintegration test was 
conducted according to a protocol advised by the ConsumerLab®, a commercial company that 
analyzes the quality of dietary supplements (36).  The solubility of FeSO4 and HIP pills was 
tested by stirring one pill in 100 mL of water at 37°C, for 30 min.  At the end of the test, which 
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was done in triplicate, none of the FeSO4 supplement remained whereas 44% of the HIP pill 
remained intact.   
Assessment of Nutrient Intake 
 Before each clinic visit (at baseline, 2-, 4-, and 8-week follow-up), participants were 
given a 3-day food/supplement log to complete beforehand and turn in during the visits.  
Participants were instructed to complete the logs on 3 non-consecutive days (2 weekdays and 1 
weekend day) prior to their visit.  Participants recorded whether they crushed the pills or took 
them whole, and whether they took them with or without food.  During the study visits, the study 
registered dietitian reviewed the log for accuracy, completeness, portion sizes, and cooking 
methods, and to clarify any uncertain food items.  The food records were analyzed using 
Nutrition Data System for Research software, version 2013 (University of Minnesota, 
Minneapolis, MN, USA), and average daily intake of nutrients was calculated.  Because the 
dietary analysis software did not provide quantity of heme iron, the heme iron in animal foods 
was calculated manually using previously published food composition tables, with information 
on the average percentage of heme iron in sources of meat products (30).  Subjects were also 
asked to bring any vitamins / supplements they were currently taking with them to each of the 
study visits.  The ingredient information, including daily dosages of iron, calcium, vitamin C, 
zinc, and copper, was recorded by the dietitian.   
Assessment of Iron Supplement Compliance and Tolerability 
 A known amount of the assigned iron supplement was provided to each patient, and it 
was enough to last until the next study visit.  Compliance was assessed via pill count and a daily 
supplement log form, in which patients tracked the times of supplement intake as well as any 
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gastrointestinal related side-effects, reasons for missed doses, and whether the iron supplement 
was taken with or without food.   
 At each of the four study visits, participants ranked gastrointestinal-related symptoms 
(nausea, constipation, diarrhea, vomiting, abdominal pain) on a scale of 1 to 5 (5 being the 
worst).  If the ranking increased at any follow-up visit compared to baseline, then the subject was 
considered to have experienced a worsening in that symptom.   
Assessment of Menstrual Blood Loss 
 Menstrual blood loss negatively impacts iron status, so this was assessed using a simple 
visual technique that has been validated previously (37).   Participants recorded the degree to 
which sanitary wear was soiled, based on a pictoral chart, and the information was used to 
determine the total blood volume of blood excreted per cycle. 
Statistical Analysis  
 Data were analyzed using R software version 3.1.2 (38).  The primary outcomes were 
changes in iron status biomarkers within groups.  Secondary outcomes included tolerability and 
compliance to the iron supplementation, as well as daily dietary and supplemental intake.  Power 
analysis used data from the aforementioned study by Rhode at al., (21) with the caveat that high 
dose vitamin C was also provided.  We found predicting an increase of 12 µg/L in serum ferritin 
required a sample size of 11 per group (α = 0.05, β = 0.8).  With guidance from the Data Safety 
Monitoring Committee, the study was stopped early because a statistically significant benefit 
was achieved in the ferrous sulfate group, and no effect was seen in any of the doses of HIP.  All 
3 doses of HIP (10.5 mg, 21 mg, and 31.5 mg) were pooled together as one HIP treatment group 
for analyses of iron status biomarkers (for hemoglobin, sTfR, ferritin, sTfR: ferritin ratios) and 
plasma hepcidin.  This was done after ensuring that for these biomarkers, the residual plots were 
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similar for the reduced (all HIP doses combined) and full (each dose of HIP as separate) models 
and that the two models were not significantly different.  TIBC was excluded from the regression 
analysis because the 3 dosages of HIP could be not be pooled together due to differences in the 
residual plots of the reduced and full models.  Two participants in the HIP group, and one 
participant in the FeSO4 group did not complete the study (see the flow diagram in Figure 1).  
We used intention to treat analysis and missing values were replaced by the last observed value 
of that variable.   
 Means and standard deviations were reported for baseline characteristics.  These were 
compared between ferrous sulfate and HIP groups using independent t-tests.  Daily intake of 
nutrients from food and supplements were compared between the two groups at both baseline 
and post intervention using the exact Wilcoxon rank-sum test.  Within group comparisons of 
nutrient intakes was done using the exact Wilcoxon signed-rank test.  The concentrations of 
CRP, serum ferritin, sTfR, sTfR: ferritin ratio and plasma hepcidin were log transformed using 
the natural log prior to statistical analysis to approximate normality, and the results were back-
transformed into the original scale.  A linear mixed model, controlling for subject level effect, 
was used to determine the effect of iron supplementation on iron status after 8 weeks.  Using the 
raw rating score of constipation, diarrhea, nausea, vomiting, and abdominal pain reported at each 
visit, the effects of the two treatments on adverse gastrointestinal side effects were determined 
using a mixed effect model for ordinal outcome data.  Statistical significance was set at P ≤ 0.05.  
In the case of the linear mixed effect model (for iron status biomarkers), the least square means 
were compared within groups and Bonferroni adjustment for two within group comparisons was 
applied.  Thus, differences in least square means were considered significant where P ≤ 0.025.  
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Results 
Baseline Characteristics of the Study Population 
 Participant flow is illustrated in Figure 1.  Recruitment began in Fall 2014, and the study 
ended in Spring 2016.  Thirty-one individuals were screened and 14 participants were enrolled 
enroll in the 8-week study. All subjects were female, and their average age at baseline was 41.5 ± 
6.9 years.  The average length of time since undergoing RYGB was 6.9 ± 3.1 years.  The study 
population was characterized to be in the mild range of obesity, with a mean BMI of 34.4 ± 5.9 
kg/m2.  All participants were classified as iron deficient, meeting at least 2 of the 4 diagnostic 
criteria.  Forty-two percent of the entire population suffered from anemia.   Six patients were 
enrolled in the ferrous sulfate treatment group, and eight in the HIP group.  Demographic and 
iron status characteristics (unadjusted values) of patients by treatment group are presented in 
Table 1.  No differences were observed between groups in age, BMI, years since surgery, CRP, 
plasma hepcidin or any of the iron status measures at baseline (P ≥ 0.05).  All of the women in 
the ferrous sulfate group were premenopausal, whereas 42% of the women in the HIP group 
were perimenopausal, (P = 0.05). 
Nutrient Intake of the Study Population 
 Daily intake of nutrients from food and supplements at baseline and at the final visit, by 
treatment group, are presented in Table 2.  There were no differences between groups in intake 
of nutrients from food and supplements (P > 0.05) at the baseline and final visits, except for the 
nutrients that patients were instructed to take in their respective treatment group.  Thus compared 
to baseline, at the final visit, participants in the HIP group increased their intakes of 
supplemental heme iron (p ≤ 0.016), and those in the ferrous sulfate group increased their intakes 
of supplemental non-heme iron (p=0.03).  No differences were seen between groups in 
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supplemental calcium and supplemental vitamin C intake, which is expected as all patients were 
instructed to take the same daily, iron-free, multivitamin /mineral supplement after screening and 
throughout the duration of the study.  Due to multivitamin/mineral supplementation that was 
implemented throughout the study, deficiencies in other nutrients, besides iron, did not occur. 
Influence of Oral Iron Supplements on Iron Status 
 Blood concentrations of ferritin, sTfR, hemoglobin, and TIBC were assessed at baseline 
and at 2, 4, and 8 weeks in RYGB patients receiving either ferrous sulfate or HIP 
supplementation.  Table 3 compares the baseline and 8-week values that have been adjusted for 
person-level random effects. As seen in Table 3, all iron status indicators improved after 8 weeks 
of ferrous sulfate supplementation (p < 0.0001). This was accompanied by a significant increase 
in plasma hepcidin concentration (p = 0.006).  Improvements were not observed in any of the 
iron status indicators following HIP supplementation, neither was there a significant change in 
plasma hepcidin concentration in this group (P > 0.025).  For both groups, there was no 
significant change in CRP concentration after intervention.  In accordance to the definition of 
iron deficiency as having two or more abnormal values, resolution of deficiency occurred in 
none of the participants receiving HIP and it occurred in 67% (4 of 6) participants receiving 
ferrous sulfate supplementation (p = 0.0094).  After supplementation with FeSO4, anemia was 
resolved in 75% of the affected participants.   
 
Iron Supplement Compliance and Tolerability 
 Compliance to taking the iron supplementation was high in both the ferrous sulfate and 
HIP treatment groups, at 95% and 94%, respectively.  The proportion of patients who received 
FeSO4 and reported worsening of constipation, diarrhea, vomiting, and abdominal pain were 
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17%, 33%, 17%, and 17%, respectively. In patients receiving HIP, 57%, 14%, and 14%, reported 
worsening of constipation, nausea, and abdominal pain, but no changes in vomiting or diarrhea 
were reported.  Although some individuals reported worsening of symptoms following 
supplementation, differences within or between groups were not significant.   
Total Blood Loss Per Menstrual Cycle 
 The volume of blood loss was 58 ± 27 mL per cycle for the ferrous sulfate group, and 32 
± 36 mL for the HIP group, and there was no difference between groups (P = 0.20).  Since more 
women in the HIP group were perimenopausal, and since blood loss was equivalent between 
groups, this demonstrates that differences in blood loss did not contribute to the difference in 
response to iron supplementation that we observed between the ferrous sulfate and HIP group.   
Discussion 
 In this study, we aimed to compare the efficacy of oral supplementation using non-heme 
iron, in the form of ferrous sulfate, versus heme iron, in the form of HIP, for improvement of 
iron status in patients who previously had undergone RYGB.  Iron status, tolerability and 
compliance to the iron supplements were measured during supplementation. The major findings 
of this study were that ferrous sulfate supplementation at the dose recommended in the clinical 
practice guidelines is effective in improving iron status.  Heme iron supplementation using the 
HIP formulation appeared to be ineffective.  Lastly, we did not find a worsening of 
gastrointestinal symptoms following supplementation with either formulation. 
 Our findings support the clinical practice guideline recommendations for treatment of 
iron deficiency after bariatric surgery.  To some extent our results are surprising given that a 
previous study showed that RYGB promotes intestinal malabsorption of both non-heme and 
heme Fe (25). This may be the case under conditions of standard dosing of iron (36 mg iron was 
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used in the previous study (25)), whereas at high doses (195 mg, used in the current study), more 
iron is absorbed. To our knowledge, no randomized controlled trial has compared oral iron 
formulations for treatment of iron deficiency in the bariatric surgery population.  However, it is 
worth noting that Brolin et al (20) tested prophylactic oral iron supplementation for prevention of 
iron deficiency in women after RYGB.  In this prospective, double-blinded study, all patients 
were randomized to receive either oral iron or placebo, one month after RYGB.  The 
investigators demonstrated that prophylactic oral iron supplements were effective in preventing 
iron deficiency from developing after RYGB.  Since we focused our study on patients who were 
already iron deficient, the findings of our current study extend that of Brolin’s to patients who 
have iron deficiency, and demonstrate that oral supplementation using ferrous sulfate is effective 
for treatment of iron deficiency after RYGB.  If the intervention was longer, we predict that iron 
deficiency and anemia would resolve in all the participants, however, it is meaningful that, for 
the majority of participants in the study, resolution of iron deficiency and associated anemia 
occurred after only 8 weeks of iron supplementation.  Interestingly, participants in the study were 
several years post-surgery, indicating that the study findings could apply to individuals at later 
timepoints relative to having surgery.  In addition, at this post-operative stage, participants were 
weight stable, which is important since weight fluctuations can affect iron homeostasis.    
 We assessed diet during the period of Fe supplementation but did not control the food 
intake of participants.  We instructed the participants to take a multivitamin and multimineral 
(MVM) supplement, throughout the study.   Even though diet was not controlled, we found that 
the dietary intake of both supplemented groups was similar.  This outcome may be a 
consequence of the randomized design of the study, or the fact that both groups consumed a 
MVM.  This ensured that the intakes of nutrients that affect iron absorption, including vitamin C, 
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and calcium were equivalent during the study.  In addition, data from our previous study 
suggests that dietary and supplemental intake of iron and vitamin C are the most important 
predictors of iron status (30).  This suggests other dietary factors, including calcium, do not play 
a major role in determining iron status, especially under conditions of high dose iron 
supplementation. 
 We also found that HIP was not effective in improving iron status in patients after 
surgery.  The effectiveness of HIP has been evaluated in populations other than bariatric surgery 
patients.  In healthy subjects, the bioavailability of HIP was compared to ferrous fumarate and 
placebo by measuring the change in serum iron concentrations at 3 and 6 hours post ingestion 
(31). The findings demonstrated that HIP was more bioavailable than ferrous fumarate when 
taken with a meal.  In a recent review article, Dull et al (32) reported that the effectiveness of 
HIP was comparable to that of oral non-heme iron supplementation in chronic kidney disease 
patients with anemia.  These results notwithstanding, our study did not find HIP to be effective in 
improving iron status after bariatric surgery. While our previous study found that high dietary 
heme iron is associated with favorable iron status following RYGB (30), the results of the 
current study do not extend this observation to a positive effect of supplemental heme iron in the 
form of HIP for treatment of iron deficiency.  Since a simple disintegration test showed the HIP 
formulation was not soluble in water we speculate that poor solubility may explain the non-
effectiveness of supplemental heme in the present study.  More research is needed to determine 
whether heme iron in other formulations could be effective for improving iron status in iron 
deficient RYGB patients.    
 A major observation in the Brolin study was that 21% of patients in the oral iron group 
did not take their iron supplement regularly (20).  In bariatric surgery patients and in the general 
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population, ferrous sulfate supplementation is known to induce adverse gastrointestinal side-
effects (29, 39).  These observations suggest that non-compliance is a major issue with oral iron 
supplementation.  For this reason gastrointestinal adverse events and compliance were strictly 
monitored in our current study.  When comparing from baseline to 8-weeks, we found no 
significant worsening of nausea, constipation, diarrhea, vomiting, and abdominal pain in subjects 
taking ferrous sulfate or HIP.  The study dietitian offered counseling to participants on ways to 
alleviate symptoms through diet or nonprescription medication.  The lack of adverse events 
could also be due to the small sample size in our study.  
 Our study has limitations, the participants, but not the investigators were blinded to the 
study intervention, it had a small sample size, and the findings may not generalizable to post-
menopausal women or to men.  We purposely recruited younger women because, due to iron loss 
via the menstrual cycle, this population has a higher risk of developing iron deficiency than post-
menopausal women.  Also, men account for a relatively small percentage of the total population 
who undergo bariatric surgery, and also a low percentage of these men develop iron deficiency 
after the procedure (26).  The study also had a small sample size, which was predicted by power 
analysis using data from a previous study (21).   
  
Conclusions 
 Our study is first to demonstrate that: 1) ferrous sulfate supplementation to treat iron 
deficiency at the dose recommended in the clinical practice guidelines is effective, and 2) heme 
iron supplementation (in a polypeptide form) is not effective for treating iron deficiency in 
RYGB patients.  Our findings are promising because they have the potential to guide future 
clinical practice in treatment of iron deficiency after bariatric surgery.  In addition, these findings 
 
 
19 
 
should stimulate future studies on oral iron supplementation in regards to improving tolerability, 
effectiveness, and compliance.  
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Figure 1.  Flow diagram outlining participants screened, eligible to enroll, and randomized, to 
receive ferrous sulfate or HIP supplementation during an 8-week, single blind, controlled trial.  
Patients who dropped out are indicated, but intention-to-treat analysis included all participants. 
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Table 1 Characteristics of patients at baseline in an 8-wk intervention of heme iron (HIP group) 
or non-heme iron (ferrous sulfate group) supplementation to treat iron deficiency after Roux-en-
Y gastric bypass surgery. 
Characteristic HIP group  
(n=8) 
Ferrous Sulfate group  
(n=6) 
p-value4 
Age, years1 40.3 ± 8.4 43.2 ± 3.9 0.571 
BMI, kg/m2 34.0 ± 5.2 34.9 ± 7.1 0.802 
Time since surgery, 
years1 
6.4 ± 2.0 7.7 ± 4.3 0.475 
Iron Status Measures    
Hemoglobin, g/dL1 12.1 ± 0.9 10.8 ± 1.9 0.195 
sTfR, mg/L2 2345 (1895, 2903) 2653 (1317, 5346) 0.577 
TIBC, µg/dL1 436 ± 55 415 ± 27 0.329 
Ferritin, µg/L2 6.6 (4.5, 9.7)3 4.9 (2.9, 8.2) 0.155 
Plasma hepcidin 
(ng/mL) 
CRP, mg/L 
1.65(1.18, 2.30) 
 
1.0 (0.5, 1.9) 
1.63(1.26, 2.09) 
 
1.5 (0.7, 3.3) 
0.937 
 
0.325 
 
1 Values are means ± SDs; BMI, body mass index; sTfR, soluble transferrin 
receptor; TIBC, total iron binding capacity; CRP, C-reactive protein 
2 Values are geometric means (range of ± 1 SD) 
3 Two subjects excluded as outliers 
4 Values refer to comparison between HIP and ferrous sulfate groups.  
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Table 2 Daily intakes of nutrients from food and supplements in patients who took heme iron (HIP group) or non-heme iron (ferrous 
sulfate group) supplements for 8-weeks1 
 HIP group (n=8) Ferrous Sulfate group (n=6) P2 
 Baseline Final Baseline Final Baseline Final 
DIET       
Calories (kcal) 1491 (1052, 1988) 1410 (1227, 1994) 1330 (1092, 1738) 1357 (1008, 1920) 0.6623 0.9307 
Fat (g) 70 (58, 91) 68 (54, 97) 69 (55, 69) 56 (50, 61) 0.6623 0.6623 
Protein (g) 57 (52, 62) 70 (61, 77) 54 (45, 63) 58 (41, 58) > 0.99 0.5368 
Calcium (mg) 817 (550, 1066) 750 (689, 1022) 600 (535, 781) 406 (378, 535) 0.5368 0.1255 
Vitamin C (mg) 39 (20, 46) 43 (17, 63) 25 (8, 36) 39 (4, 47)  0.7922 0.5368 
Phytic acid  285 (193, 446) 333 (159, 416) 303 (233, 472) 320 (303, 386) > 0.99 0.7922 
Heme iron (mg) 1.4 (0.8, 2.0) 1.9 (1.4, 2.5) 1.1 (1.1, 1.7) 1.3 (1.0, 2.4) 0.7922 0.6623 
Non-heme iron 
(mg) 
6.9 (5.2, 10.9) 7.6 (5.3, 11.7) 6.6 (4.8, 7.7) 6.5 (4.2, 8.3) 0.7922 0.5368 
Total iron (mg) 9.6 (7.2, 11.9) 9.1 (6.9, 14.5) 7.8 (6.5, 9.6) 7.8 (6.6, 8.9) 0.329 0.5368 
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SUPPLEMENT       
Non-heme iron 
(mg) 
0 (0, 0) 0 (0, 0) 0 (0, 0) 193 (186, 193)* 0.4545 0.0022 
Heme iron (mg) 0 (0, 0) 30.3 (28.4, 76.5)* 0 (0, 0) 0 (0, 0) > 0.99 0.0043 
Calcium (mg) 200 (200, 673) 200 (200, 200) 200 (171, 200) 143 (143, 200) 0.3182 0.2532 
Vitamin C (mg) 75 (75, 75) 75 (75, 75) 75 (64, 75) 54 (54, 75) 0.1212 0.0606 
 
1 Values are medians (1st and 3rd quartiles). *Within group difference from baseline, P ≤ 0.05. HIP, Heme iron polypeptide 
2 Values refer to comparison between HIP and ferrous sulfate groups
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Table 3 Least Square Means: Iron status changes from baseline to final, after controlling for 
person-level random effects, in an 8-week intervention comparing ferrous sulfate and HIP 
supplementation1 
Group Biomarker Baseline Final P-value 
 
 
FeSO4 
(n=6) 
Hemoglobin 
(g/dL) 
10.8 (9.8, 11.9) 13.0 (11.9, 14.0) < 0.0001 
sTfR 
(µg/L) 
2111 (1556, 2864) 1270 (934, 1734) < 0.0001 
Ferritin 
(µg/L) 
4.9 (3.4, 7.2) 15.5 (10.6, 22.6) < 0.0001 
sTfR:ferritin ratio  542 (273, 1086) 103 (51, 204) < 0.0001 
Plasma hepcidin 
(ng/mL)  
1.63 (1.21, 2.18) 2.45 (1.83, 3.28) 0.006 
CRP mg/L 1.53 (0.65, 3.61) 1.66 (0.70, 3.89) 0.81 
 
 
HIP 
(n=8) 
Hemoglobin 
(g/dL) 
12.1 (11.3, 13.0) 12.2 (11.3, 13.1) 0.597 
sTfR 
(µg/L) 
2345 (1845, 2981) 2528 (1978, 3229) 0.185 
Ferritin2 
(µg/L) 
6.6 (4.5, 9.7) 6.1 (4.2, 8.9) 0.575 
sTfR:ferritin 
ratio2  
330 (165, 658) 380 (191, 757) 0.428 
Plasma hepcidin 1.80 (1.40, 2.30) 1.72 (1.35, 2.21) 0.708 
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(ng/mL) 
CRP mg/L 0.98 (0.48, 2.02) 1.08 (0.53, 2.23) 0.71 
 
1Values are means (95% CI). Difference considered significant if P ≤ 0.025 (Bonferoni 
adjustment for two comparisons).  CRP, C-reactive protein; FeSO4, ferrous sulfate; HIP, heme 
iron polypeptide; sTfR, soluble transferrin receptor.  Baseline and 8-week values have been 
adjusted for person-level random effects.  All variables except hemoglobin were log 
transformed before linear mixed models were performed and the least square means (95% CI) 
were back-transformed into the original scale.  Outliers were excluded variable by variable. 
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